PCSK9 inhibitor – Medxy AI

Evolocumab Significantly Reduces Mortality in High-Risk Patients Without Prior Heart Attack or Stroke: Insights from the VESALIUS-CV Trial

By MedXY 09/08/2026

The VESALIUS-CV trial demonstrates that evolocumab lowers all-cause and cardiovascular mortality in patients with high cardiovascular risk but no prior myocardial infarction or stroke, highlighting its survival benefits in primary prevention.

Cardiology news

Enlicitide: A Breakthrough Oral PCSK9 Inhibitor Offering Superior LDL-C Reduction Compared to Established Oral Nonstatin Therapies

By MedXY 08/11/2026

This phase 3 trial demonstrates that the oral PCSK9 inhibitor enlicitide achieves significantly greater LDL-C reduction than bempedoic acid, ezetimibe, or their combination in statin-treated adults at elevated cardiovascular risk, with comparable safety profiles.

Cardiology news

Evolocumab in Patients With Prior Percutaneous Coronary Intervention and No Prior MI: Results From the VESALIUS-CV Trial

By MedXY 05/19/2026

In patients with prior PCI but no prior MI, evolocumab significantly lowered LDL-C and reduced major cardiovascular events, including myocardial infarction and urgent revascularization, supporting intensive lipid lowering after coronary intervention.

Cardiology news

Laroprovstat, the First Oral Small-Molecule PCSK9 Inhibitor for Hypercholesterolemia: Results From a Phase 1 Trial

By MedXY 05/15/2026

Laroprovstat, an investigational oral PCSK9 inhibitor, was well tolerated and produced substantial LDL cholesterol reductions, especially when combined with rosuvastatin, supporting further development for hypercholesterolemia.

Cardiology Internal Medicine news

PCSK9 Inhibition Lowers LDL Cholesterol in Heterozygous Familial Hypercholesterolemia Regardless of LDL Receptor Variant Function

By MedXY 05/03/2026

In a pooled nonrandomized phase 3 analysis, monthly lerodalcibep reduced LDL-C by about 50% in heterozygous familial hypercholesterolemia, with similar efficacy across LDLR functional variant categories and broad attainment of guideline-based LDL-C goals.

Cardiology Diabetes & Endocrinology news

Evolocumab Prevents First Major Cardiovascular Events in High‑Risk Patients without Prior MI or Stroke

By MedXY 11/13/2025

In VESALIUS-CV, evolocumab reduced first major adverse cardiovascular events by ~25% (HR 0.75) versus placebo in patients with atherosclerosis or diabetes without prior myocardial infarction or stroke, with modest absolute risk reductions and no new safety signals over 4.6 years.

Cardiology Clinical Updates Diabetes & Endocrinology news Specialties

Evolocumab’s Impact on Cardiovascular Risk in Type 1 Diabetes: Insights from the FOURIER Trial

By MedXY 08/24/2025

The FOURIER trial reveals intensive LDL-C lowering with evolocumab substantially reduces cardiovascular events in type 1 diabetes patients with ASCVD, highlighting significant clinical benefit and urging further dedicated research.